The initial success of Sildenafil undeniably revolutionized the medication landscape, but placing funds in companies heavily reliant on off-patent versions presents a uncertain picture. While early profits were substantial, the cessation of patents and the appearance of less expensive alternatives have eroded the customer base. Consequently, a thor